In an interesting novel work that combined an epigenetic inhibitor—AZD5153—and a BTKi—acalabrutinib, in the pre-clinical models of ABC-DLBCL, it was observed that AZD5153 enhanced the efficacy of BTKi, operating through PAX5 (TF for BCR signaling genes) and BCR itself. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.